Scarica l'app Stockscreener
56.12
1.15%
0.64
Dopo l'orario di chiusura:
56.12
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Franklin Resources Inc. Has $13.03 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Barclays PLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children - MarketWatch
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire
Rhythm Pharma's IMCIVREE Wins FDA Approval for Rare Obesity Treatment in Young Children - StockTitan
Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals - Benzinga
Oppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - Nasdaq
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wellington Management Group LLP - MarketBeat
(RYTM) Trading Signals - Stock Traders Daily
State Street Corp Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Fmr LLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
BNP Paribas Financial Markets Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Frazier Life Sciences Management L.P. Acquires 45,648 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
National Bank of Canada FI Has $17.89 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 11,058 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals: A Key Year Ahead (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities - Yahoo Finance
(RYTM) Technical Data - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Goldman Sachs raises Rhythm Pharmaceuticals stock target by 12%, maintains Buy rating - Investing.com Canada
HighVista Strategies LLC Buys 23,064 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Defici - GlobeNewswire
Rhythm Pharma's IMCIVREE Gets UK Approval for Rare Obesity in Children as Young as 2 | RYTM Stock News - StockTitan
12,386 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Intech Investment Management LLC - MarketBeat
Alkeon Capital Management LLC Buys 167,700 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Victory Capital Management Inc. Has $953,000 Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Algert Global LLC - MarketBeat
25,063 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Penserra Capital Management LLC - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Loomis Sayles & Co. L P Invests $33.35 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals retains stock target, buy rating on new data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' (RYTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts - Benzinga
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Provides Information to the Shareholders - Marketscreener.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Primecap Management Co. CA - MarketBeat
First Week of RYTM July 2025 Options Trading - Nasdaq
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide - GlobeNewswire
Rhythm Pharma: New Drug Shows 9.6% Weight Loss in Pediatric Obesity Treatment Study | RYTM Stock News - StockTitan
Perceptive Advisors LLC's Strategic Acquisition in Rhythm Pharma - GuruFocus.com
(RYTM) Proactive Strategies - Stock Traders Daily
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - The Manila Times
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock - Investing.com
Rhythm Pharmaceuticals EVP sells $4.43m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP sells $4.43m in stock - Investing.com
Rhythm Pharmaceuticals Announces Publication of Results - GlobeNewswire
Rhythm Pharma's Obesity Drug Shows 83% Success in Phase 3 Trial, FDA Priority Review Set | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals Awards 15,750 RSUs to New Employees in Talent Acquisition Push | RYTM Stock News - StockTitan
PRIMECAP Management Adjusts Stake in Rhythm Pharmaceuticals - GuruFocus.com
Goldman Sachs Group Inc Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):